Department of Pharmaceutical Sciences, Doctor Hari Singh Gour Vishwavidyalaya, Sagar, MP, India.
Andrologia. 2012 May;44 Suppl 1:160-74. doi: 10.1111/j.1439-0272.2010.1155.x. Epub 2011 Jun 8.
The aim of the present study was to find out whether Ganoderma lucidum (GL) can be used as a clinically effective medicine for the management of prostatic hyperplasia. In vitro studies were conducted to assess the 5α-reductase inhibitory potential of GL. A biochemical marker viz. β-sitosterol was identified and characterised in the extracts utilising high-performance thin-layer chromatography. Testosterone (3 mg kg(-1) s.c.) was administered to the rats along with the test extracts (10, 20 and 50 mg kg(-1) p.o.) and β-sitosterol (10 and 20 mg kg(-1) p.o.) for a period of 28 days. Finasteride was used as a positive control (1 mg kg(-1) p.o.). GL extracts attenuated the increase in the prostate/body weight ratio induced by testosterone. Petroleum ether extract exhibiting the best activity. Ethanolic extract also exhibited significant activity. The urine output also improved significantly, which emphasise the clinical implications of the study. Testosterone levels measured weekly and prostate-specific antigen (PSA) levels measured at the end of the study also support our claims. The PSA levels decreased in the extract-treated groups, indicating their usefulness in the treatment of benign prostatic hyperplasia. Histological studies have shown a considerable improvement in the prostatic histoarchitecture in the extract-treated groups when compared to the testosterone-treated group.
本研究旨在探讨灵芝（Ganoderma lucidum）是否可作为治疗前列腺增生的有效药物。我们进行了体外研究以评估灵芝对 5α-还原酶的抑制潜力。利用高效薄层色谱法对提取物进行鉴定和分析，确定并鉴定出生化标志物 β-谷甾醇。将灵芝提取物（10、20 和 50 mg/kg，p.o.）和 β-谷甾醇（10 和 20 mg/kg，p.o.）与睾酮（3 mg/kg，s.c.）一起给大鼠连续给药 28 天，以此作为实验模型。非那雄胺（1 mg/kg，p.o.）被用作阳性对照。灵芝提取物可抑制睾酮诱导的前列腺/体重比增加。石油醚提取物显示出最佳活性，乙醇提取物也显示出显著的活性。尿液输出也显著改善，这强调了该研究的临床意义。每周测量的睾酮水平和研究结束时测量的前列腺特异性抗原（PSA）水平也支持我们的观点。在提取物治疗组中，PSA 水平下降，表明它们在治疗良性前列腺增生方面具有一定的作用。组织学研究表明，与睾酮治疗组相比，提取物治疗组的前列腺组织形态学有了显著改善。
